How to Adequately Treat Pseudomonas aeruginosa Infections
Abstract Pseudomonas aeruginosa is an opportunistic pathogen and a leading cause of hospital-acquired infections, particularly among immunocompromised patients, the critically ill, and those with indwelling devices or chronic lung disease such as cystic fibrosis. Its intrinsic resistance profile, capacity to acquire additional resistance to new antibiotics, and propensity to form protective biofilms make infections difficult to eradicate and prone to recurrence. With therapeutic options increasingly limited—often requiring last-line antibiotics—there is an urgent need for innovative strategies to counter growing resistance. This review provides a comprehensive overview of current approaches to the treatment of P. aeruginosa and highlights emerging therapies under active development.
Authors
- Daniel Reynolds
- Marin H. Kollef (ORCID: https://orcid.org/0000-0003-0671-0751)
- Alex S. Hartlage (ORCID: https://orcid.org/0000-0002-8414-2959)
Institutions
- Washington University in St. Louis (US)
Publication Details
- Journal
- Seminars in Respiratory and Critical Care Medicine
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1055/a-2991-9004
- Primary Topic
- Bacterial biofilms and quorum sensing
- Type
- article
- Field-Weighted Citation Impact
- 0.00